Nanjing Well Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the research, development, production, and sales of pharmaceutical excipients and synthetic lubricating base oils. The Company's products mainly include mechanical synthetic lubricating base oils, non-mechanical synthetic lubricating base oils, injectable pharmaceutical excipients, and non-injectable pharmaceutical excipients. The Company distributes its products within the domestic market and to overseas markets.

Employees

718

Sector

Oil & Gas Refining and Marketing

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	CN¥26.64	-1.52%	1,973,400
29/10/26	CN¥27.05	-1.81%	2,149,610
28/10/26	CN¥27.55	+5.92%	2,258,000
27/10/26	CN¥26.01	-3.09%	1,340,760
26/10/26	CN¥26.84	+0.60%	1,466,100

End-of-day quote Shanghai S.E.

More quotes

End-of-day quote Shanghai S.E. 29/10/2026			5-day change	1st Jan Change
27.05 ^CNY	-1.81%		+2.97%	+3.96%

10-28	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	CI

Market Cap	3.66B 550M 492M 454M 411M 769M 52.35B 781M 5.42B 2.16B 27.4B 2.06B 2.02B 86.77B	P/E 2024	22.7x	P/E 2025	23.4x
Enterprise Value	3.81B 572M 513M 473M 428M 800M 54.5B 813M 5.64B 2.25B 28.53B 2.15B 2.1B 90.35B	EV / Sales 2024	2.75x	EV / Sales 2025	2.75x
Free-Float	38.51%	Yield 2024	1.63%	Yield 2025	2.31%

10-28	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026	CI
10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. authorizes a Buyback Plan.	CI
10-01	Nanjing Well Pharmaceutical Group Co.,Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	CI
08-21	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-16	Nanjing Well Pharmaceutical Group Co.,Ltd. signed a property rights transaction contract to acquire 50.98% stake in Lianyungang Wantai Pharmaceutical Excipients Technology Co., Ltd. from Tianjin Boguang Medical Biotechnology Development Co., Ltd. for CNY 19.4 million.	CI
06-10	Nanjing Well Pharmaceutical Completes Updating Business Scope Registration	MT
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Nanjing Well Pharmaceutical Group Co.,Ltd. announces Annual dividend, payable on June 05, 2026	CI
29/10/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
19/08/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
22/04/25	Nanjing Well Pharmaceutical Group Co.,Ltd. announces Annual dividend, payable on June 13, 2025	CI
21/04/25	Nanjing Well Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

1 day	-1.81%
1 week	+2.97%
Current month	-1.49%
1 month	-0.59%
3 months	+16.49%
6 months	+0.07%
Current year	+3.96%

Nanjing Well Pharmaceutical Group Co.,Ltd. Stock

Stocks

603351

CNE100003JD4

Oil & Gas Refining and Marketing

Valuation: Nanjing Well Pharmaceutical Group Co.,Ltd.

Chart: Nanjing Well Pharmaceutical Group Co.,Ltd.

Latest news: Nanjing Well Pharmaceutical Group Co.,Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Nanjing Well Pharmaceutical Group Co.,Ltd.

Latest insider transactions

Other Oil & Gas Refining and Marketing

Financials

Company Profile

Quotes

1 week	25.98	27.88
1 month	25.03	29.54
Current year	21.9	29.54
1 year	21.9	30.8
3 years	17.65	33.34
5 years	17.65	42.62
10 years	17.08	42.62

Manager	Title	Age	Since
Ren Rong Wu CEO	Chief Executive Officer	63	25/03/2017
Qun Song Tang DFI	Director of Finance/CFO	59	25/03/2017
Zheng Song Gao CTO	Chief Tech/Sci/R&D Officer	61	25/03/2017

Director	Title	Age	Since
Ren Rong Wu CHM	Chairman	63	25/03/2017
Zheng Song Gao BRD	Director/Board Member	61	25/03/2017
Xin Guo Chen BRD	Director/Board Member	58	25/03/2017

	2024	2025
Net sales	1.3B 195M 174M 161M 146M 272M 18.53B 276M 1.92B 765M 9.7B 730M 715M 30.71B	1.34B 200M 179M 166M 150M 280M 19.08B 285M 1.97B 788M 9.98B 752M 736M 31.62B
Net income	146M 21.97M 19.68M 18.16M 16.43M 30.72M 2.09B 31.22M 217M 86.41M 1.09B 82.45M 80.7M 3.47B	151M 22.65M 20.29M 18.72M 16.94M 31.68M 2.16B 32.19M 223M 89.09M 1.13B 85.01M 83.2M 3.58B
Net Debt	234M 35.12M 31.46M 29.02M 26.26M 49.11M 3.34B 49.9M 346M 138M 1.75B 132M 129M 5.54B	151M 22.63M 20.27M 18.7M 16.92M 31.64M 2.15B 32.15M 223M 89M 1.13B 84.92M 83.12M 3.57B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NANJING WELL PHARMACEUTICAL GROUP CO.,LTD.	-1.81%	+2.97%	-1.31%	+2.93%	550M
EXXONMOBIL HOLDINGS CORPORATION	+1.52%	+2.53%	+63.79%	+77.41%	754B
RELIANCE INDUSTRIES LTD	-0.21%	-2.11%	-21.74%	+0.75%	166B
BP PLC	+0.29%	-1.83%	+39.96%	+19.01%	129B
MARATHON PETROLEUM CORPORATION	+2.10%	-3.95%	+124.48%	+199.03%	121B
PHILLIPS 66	+2.65%	-0.40%	+105.78%	+150.85%	107B
VALERO ENERGY CORPORATION	+2.14%	-6.38%	+130.76%	+215.94%	107B
CHINA PETROLEUM & CHEMICAL CORPORATION	+6.22%	+9.08%	+18.08%	+20.42%	95.68B
SUNCOR ENERGY INC.	+1.07%	-1.08%	+97.95%	+145.11%	90.88B
IMPERIAL OIL LIMITED	+0.62%	-1.68%	+45.14%	+132.23%	63.5B
Average	+1.48%	-1.19%	+60.29%	+96.37%	163.46B
Weighted average by Cap.	+1.59%	+0.17%	+63.35%	+90.48%